CN117298177B - Natural immunomodulator and preparation method thereof - Google Patents
Natural immunomodulator and preparation method thereof Download PDFInfo
- Publication number
- CN117298177B CN117298177B CN202311595881.1A CN202311595881A CN117298177B CN 117298177 B CN117298177 B CN 117298177B CN 202311595881 A CN202311595881 A CN 202311595881A CN 117298177 B CN117298177 B CN 117298177B
- Authority
- CN
- China
- Prior art keywords
- valienamine
- fatty acid
- hexoside
- preparation
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 239000002955 immunomodulating agent Substances 0.000 title claims abstract description 33
- 229940121354 immunomodulator Drugs 0.000 title claims abstract description 33
- 230000002584 immunomodulator Effects 0.000 title claims abstract description 27
- 238000000855 fermentation Methods 0.000 claims abstract description 42
- 230000004151 fermentation Effects 0.000 claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 230000000813 microbial effect Effects 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 239000012453 solvate Substances 0.000 claims abstract description 5
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 238000002156 mixing Methods 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000006228 supernatant Substances 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 18
- 239000000376 reactant Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 238000003756 stirring Methods 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 12
- XPHOBMULWMGEBA-UHFFFAOYSA-N Valienamine Natural products NC1C=C(CO)C(O)C(O)C1O XPHOBMULWMGEBA-UHFFFAOYSA-N 0.000 claims description 11
- 150000004665 fatty acids Chemical class 0.000 claims description 11
- XPHOBMULWMGEBA-VZFHVOOUSA-N valienamine Chemical compound N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O XPHOBMULWMGEBA-VZFHVOOUSA-N 0.000 claims description 11
- 241000607528 Aeromonas hydrophila Species 0.000 claims description 10
- 241000194106 Bacillus mycoides Species 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 9
- 239000000194 fatty acid Substances 0.000 claims description 9
- 229930195729 fatty acid Natural products 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 claims description 8
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 claims description 8
- 241000223260 Trichoderma harzianum Species 0.000 claims description 8
- 239000000287 crude extract Substances 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229940068041 phytic acid Drugs 0.000 claims description 8
- 235000002949 phytic acid Nutrition 0.000 claims description 8
- 239000000467 phytic acid Substances 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims description 6
- 101150065749 Churc1 gene Proteins 0.000 claims description 6
- 102100038239 Protein Churchill Human genes 0.000 claims description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 238000001694 spray drying Methods 0.000 claims description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000007791 liquid phase Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 3
- 229960004488 linolenic acid Drugs 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 150000003863 ammonium salts Chemical class 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims description 2
- 150000007529 inorganic bases Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 229910052788 barium Inorganic materials 0.000 claims 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 12
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 7
- 230000007365 immunoregulation Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 12
- 210000001072 colon Anatomy 0.000 description 10
- 238000004321 preservation Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 241000830536 Tripterygium wilfordii Species 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 235000015398 thunder god vine Nutrition 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000002337 glycosamines Chemical class 0.000 description 4
- 229940124644 immune regulator Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DFBIRQPKNDILPW-CIVMWXNOSA-N Triptolide Chemical compound O=C1OCC([C@@H]2C3)=C1CC[C@]2(C)[C@]12O[C@H]1[C@@H]1O[C@]1(C(C)C)[C@@H](O)[C@]21[C@H]3O1 DFBIRQPKNDILPW-CIVMWXNOSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- YKUJZZHGTWVWHA-UHFFFAOYSA-N triptolide Natural products COC12CC3OC3(C(C)C)C(O)C14OC4CC5C6=C(CCC25C)C(=O)OC6 YKUJZZHGTWVWHA-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 101000998145 Mus musculus Interleukin-17A Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 241000545405 Tripterygium Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/37—Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the technical field of natural medicines, in particular to a natural immunomodulator and a preparation method thereof, wherein the natural immunomodulator comprises a microbial fermentation preparation, a fatty acid-valienamine-hexoside compound or pharmaceutically acceptable salt, solvate or hydrate thereof. The invention also provides a preparation method of the natural immunomodulator, and a biological activity experiment shows that the natural immunomodulator has an immunoregulation effect, can inhibit the expression of TNF-alpha and IL-17, can be used for preventing and/or treating immune related diseases, and has a good attenuation effect.
Description
Technical Field
The invention relates to the technical field of natural medicines, in particular to a natural immunomodulator and a preparation method thereof.
Background
The balance of the immune system is critical to physical health and is susceptible to immune disease when it is broken. Tumors and infections are associated with immune hypofunction in the body; the immune response may also cause organ transplant immune rejection, allergy and autoimmune diseases. Immunomodulators can treat immune disorders caused by immune dysfunction by modulating the immune response of the body. For diseases such as tumor and infection related to hypoimmunity, the intervention can be performed by adopting regulator for enhancing organism immunity. For diseases related to the excessive immune reaction of the organism, such as organ transplantation immune rejection, allergy, autoimmune diseases and the like, immunosuppressants can be used for improving disease symptoms and prognosis. The tripterygium wilfordii is a perennial vine of tripterygium in the family of the dulidae, has the effects of clearing heat and detoxicating, detumescence, removing food retention, disinsection, stopping bleeding and the like, has remarkable immunosuppressive activity, and is used for treating autoimmune diseases such as rheumatoid arthritis, chronic nephritis, lupus erythematosus, psoriasis and the like in the beginning of the 50 th century. The active ingredients of radix Tripterygii Wilfordii include triptolide, tripterine, etc. Although having remarkable pharmacological activity, the composition has strong killing effect on normal cells, poor water solubility and narrow therapeutic window, and greatly limits clinical application. Therefore, the pharmacological activity of the tripterygium wilfordii is improved or maintained, the toxicity of the tripterygium wilfordii to normal cells is reduced, the therapeutic index of the tripterygium wilfordii is improved, and the development of a novel high-efficiency low-toxicity immunomodulator is a technical problem to be solved.
Disclosure of Invention
Aiming at the technical problems, the invention provides a natural immunomodulator and a preparation method thereof, wherein microorganisms are adopted to ferment traditional Chinese medicines with immunoregulation effects such as tripterygium wilfordii, and the natural immunomodulator has the effects of synergism, detoxification and the like; the trichoderma harzianum can decompose cellulose into glucose for use by aeromonas hydrophila and bacillus mycoides, and is converted into amino sugar with an immunoregulation function, the amino sugar is combined with valienamine by glycosidic bond, and then a fatty acid chain is introduced, so that the obtained fatty acid-valienamine-hexoside has stronger biological affinity, and the immunoregulation effect can be improved.
The invention is realized by the following technical scheme:
a natural immunomodulator comprises microbial fermentation preparation and fatty acid-valienamine-hexoside.
Further, the preparation method of the microbial fermentation preparation comprises the following steps:
(1) Mixing and cleaning radix Tripterygii Wilfordii, radix Paeoniae alba and Corni fructus at a mass ratio of 5:1:1, drying and pulverizing at 55deg.C, sieving with 80 mesh sieve, mixing with water, sterilizing at 121deg.C for 30min, and adding K 2 HPO 4 、KH 2 PO 4 NaCl and MgSO 4 Obtaining a fermentation medium;
(2) Inoculating Trichoderma harzianum, aeromonas hydrophila and bacillus mycoides into the fermentation culture medium obtained in the step (1), wherein the inoculum size is 5%, the fermentation temperature is 26-30 ℃, and the shaking table is cultivated for 96 hours at the rotation speed of a shaking table of 150-200r/min to obtain fermentation liquor;
(3) Centrifuging the fermentation liquor obtained in the step (2) for 10min at 3000r/min, carrying out solid-liquid separation to obtain a precipitate and a supernatant I, placing the precipitate in a sterile tube, adding anhydrous methanol, carrying out ultrasonic extraction at 30 ℃ and 500W for 3-4h, cooling to room temperature, centrifuging for 10min at 12000r/min, separating to obtain a supernatant II, repeatedly extracting for 3 times, mixing the supernatant II each time, filtering the supernatant with a microporous membrane of 0.22 mu m to obtain a filtrate, freeze-drying the filtrate, and grinding the filtrate into powder to obtain the microbial fermentation preparation.
Further, the K is obtained in the step (1) 2 HPO 4 、KH 2 PO 4 NaCl and MgSO 4 The addition amounts of (C) were 0.7 g/L, 0.3 g/L, 0.5g/L and 0.5g/L, respectively.
Further, the trichoderma harzianum preservation address in the step (2) is China general microbiological culture collection center, and the preservation number is CGMCC 5.1213; the preservation address of aeromonas hydrophila is China general microbiological culture collection center, and the preservation number is CGMCC 1.2017; the preservation address of the bacillus mycoides is China general microbiological culture collection center, and the preservation number is CGMCC 1.10168; the strains are all disclosed strains.
Further, the mass-to-volume ratio of the precipitate to the anhydrous methanol in the step (3) is 2g to 15mL.
Further, the fatty acid-valienamine-hexoside includes a fatty acid-valienamine-hexoside compound or a pharmaceutically acceptable salt, solvate or hydrate thereof.
Further, the structural formula of the fatty acid-valienamine-hexoside compound is shown as formula 1:
formula 1.
Further, the R1 group in formula 1 is CH 3 (CH 2 ) 4 CH=CHCH 2 CH=CH(CH 2 ) 7 —、CH 3 (CH 2 ) 4 CH=CHCH 2 CH=CHCH 2 CH=CH(CH 2 ) 7 -and CH 3 (CH 2 ) 4 (CH=CH-CH 2 ) 4 (CH 2 ) 2 -at least one of them.
Further, the preparation method of the fatty acid-valienamine-hexoside compound comprises the following steps:
I. mixing valienamine and fatty acid in a molar ratio of 1:1, adding deionized water, adjusting pH to 7.5-8 with sodium bicarbonate, maintaining the temperature at 40-50deg.C, and stirring for 30min to obtain a reactant I;
adding the supernatant I and phytic acid obtained in the step (3) into the reactant I obtained in the step I, regulating the pH to 10-11 by using 1mol/L NaOH, stirring and heating to 100 ℃, heating for 4 hours, concentrating to 20% of the original volume at 60 ℃, and then spray drying to obtain powder;
III, mixing the powder obtained in the step II with ethyl acetate according to the mass ratio of 1:3, stirring for 1h, filtering, and concentrating the filtrate to dryness under the absolute pressure of 0.08MPa to obtain a crude extract;
and IV, performing silica gel column chromatography on the crude extract obtained in the step III, eluting with eluent with the volume ratio of cyclohexane to ethyl acetate of 70:30, performing medium-low pressure liquid-phase ODS column chromatography, eluting with eluent with the volume ratio of methanol to water of 90:10, concentrating to dryness under the absolute pressure of 0.08MPa, and eluting with the flow rate of 3mL/min to obtain the fatty acid-valienamine-hexoside compound.
Further, the mass ratio of valienamine to deionized water in the step I is 1:10.
Further, the volume ratio of the reactant I, the supernatant I and the phytic acid in the step II is 20:60:1.
Further, the fatty acid is at least one of linoleic acid, alpha-linolenic acid and tetraarachidonic acid.
Further, the pharmaceutically acceptable salt is a salt of the compound of formula 1 with an organic or inorganic base.
Still further, the salt formed is a sodium salt, potassium salt, calcium salt, iron salt, magnesium salt, zinc salt, aluminum salt, barium salt, or ammonium salt.
Further, the pharmaceutically acceptable solvate is a solution formed by dissolving the compound of formula 1 in a solvent.
Further, the pharmaceutically acceptable hydrate is a hydrate formed by combining the compound of formula 1 with water molecules through covalent bonds.
The invention also provides a preparation method of the natural immune regulator, which is characterized by comprising the following steps: uniformly mixing the microbial fermentation preparation and fatty acid-valienamine-hexoside in a mass ratio of 5:1 in a mixer to prepare the natural immunomodulator.
Further, the natural immunomodulator may be various clinically acceptable dosage forms including injections such as intravenous emulsion, oral solid preparations such as tablets, capsules, granules and the like.
Further, the natural immunomodulator contains an effective dose of microbial fermentation preparation and fatty acid-valienamine-hexoside.
Compared with the prior art, the invention has the following beneficial effects:
according to the invention, trichoderma harzianum, aeromonas hydrophila and bacillus mycoides are adopted to ferment traditional Chinese medicines with immunosuppressive effects such as tripterygium wilfordii, after the action of microorganisms, substances such as cellulose, lignin and the like in the cell walls of the traditional Chinese medicines are degraded, and active ingredients are released; the active ingredients of the traditional Chinese medicine are hydrolyzed into micromolecular substances, which is favorable for the absorption of organisms and enhances the drug effect. Meanwhile, after microbial fermentation, the toxicity of the traditional Chinese medicine is reduced, and the cytotoxicity of active ingredients such as triptolide and tripterine can be reduced, so that the toxic and side effects are reduced. And meanwhile, the components such as cellulose and protein in the traditional Chinese medicine can be used by microorganisms to promote the growth and propagation of the microorganisms, the traditional Chinese medicine and the microorganisms act synergistically and complement each other, the traditional Chinese medicine is fermented through the growth metabolism and bioconversion of the microorganisms, the efficacy can be improved, the toxicity and toxic and side effects of the traditional Chinese medicine are reduced, and the fermented product shows the efficacy higher than the additive efficacy of the drug property matrixes. In addition, trichoderma harzianum can produce cellulase, decompose cellulose into glucose for the utilization of aeromonas hydrophila and bacillus mycoides, on one hand, the growth and the reproduction of aeromonas hydrophila and bacillus mycoides can be promoted, on the other hand, the aeromonas hydrophila can convert glucose into galactosamine, the bacillus mycoides can convert glucose into glucosamine, both galactosamine and glucosamine are aminosugars, the immunoregulation function is realized, the aminosugars and valienamine are combined through glycosidic bonds, the product has the effects of resisting inflammation and regulating immunity, and the fatty acid chain is introduced, so that the obtained fatty acid-valienamine-hexoside has stronger biological affinity and can improve the immunoregulation effect.
Drawings
In order to more clearly illustrate the invention or the technical solutions of the prior art, the drawings which are used in the description of the embodiments or the prior art will be briefly described, it being obvious that the drawings in the description below are only of the invention and that other drawings can be obtained from them without inventive effort for a person skilled in the art.
FIG. 1 is a nuclear magnetic resonance spectrum of a linoleic acid-valienamine-hexoside compound according to example 3 of the invention, wherein A is 1 H-NMR chart, B is 13 C-NMR chart;
FIG. 2 is a structural formula diagram of a linoleic acid-valienamine-hexoside compound according to example 3 of the present invention;
FIG. 3 is a graph showing the effect of the natural immunomodulators described in example 5 and comparative examples 1-2 of the invention on TNF- α levels in colon tissue of mice in each group;
FIG. 4 is a graph showing the effect of the natural immunomodulators described in example 5 and comparative examples 1-2 of the invention on IL-17 content in colon tissue of mice in each group;
FIG. 5 is a graph showing the effect of the natural immunomodulator according to example 5 and comparative examples 1-2 on L02 cell viability of human normal hepatocytes.
Detailed Description
The present invention will be further described in detail with reference to the following specific examples, but the present invention is not limited to the following examples, for the purpose of making the objects, technical solutions and advantages of the present invention more apparent.
Unless otherwise specified, the chemical reagents involved in the invention are purchased commercially, and the strain is a disclosed strain.
Example 1: the embodiment provides a microbial fermentation preparation, and a preparation method of the microbial fermentation preparation comprises the following steps:
(1) Mixing and cleaning radix Tripterygii Wilfordii, radix Paeoniae alba and Corni fructus at a mass ratio of 5:1:1, drying and pulverizing at 55deg.C, sieving with 80 mesh sieve, mixing with water, sterilizing at 121deg.C for 30min, and adding K 2 HPO 4 、KH 2 PO 4 NaCl and MgSO 4 The addition amounts are respectively 0.7 g/L, 0.3 g/L, 0.5g/L and 0.5g/L, so as to obtain a fermentation culture medium;
(2) Inoculating Trichoderma harzianum, aeromonas hydrophila and bacillus mycoides into the fermentation culture medium obtained in the step (1), wherein the inoculation amount is 5%, the fermentation temperature is 30 ℃, and the shaking table is used for shake cultivation for 96 hours at the rotation speed of a shaking table of 200r/min to obtain fermentation liquor;
(3) Centrifuging the fermentation liquor obtained in the step (2) at 3000r/min for 10min, carrying out solid-liquid separation to obtain a precipitate and a supernatant I, placing the precipitate in a sterile tube, adding anhydrous methanol, carrying out ultrasonic extraction for 4h at 30 ℃ and 500W, cooling to room temperature, centrifuging at 12000r/min for 10min, separating to obtain a supernatant II, repeatedly extracting for 3 times, mixing the supernatant II each time, filtering through a microporous filter membrane of 0.22 mu m to obtain a filtrate, freeze-drying the filtrate, and grinding the filtrate into powder to obtain the microbial fermentation preparation.
Example 2: the embodiment provides a microbial fermentation preparation, and a preparation method of the microbial fermentation preparation comprises the following steps:
(1) Mixing and cleaning radix Tripterygii Wilfordii, radix Paeoniae alba and Corni fructus at a mass ratio of 5:1:1, drying and pulverizing at 55deg.C, sieving with 80 mesh sieve, mixing with water, sterilizing at 121deg.C for 30min, and adding K 2 HPO 4 、KH 2 PO 4 NaCl and MgSO 4 The addition amounts are respectively 0.7 g/L, 0.3 g/L, 0.5g/L and 0.5g/L, so as to obtain a fermentation culture medium;
(2) Inoculating Trichoderma harzianum, aeromonas hydrophila and bacillus mycoides into the fermentation culture medium obtained in the step (1), wherein the inoculation amount is 5%, the fermentation temperature is 26 ℃, and the shaking table is cultivated for 96 hours at the rotation speed of a shaking table of 150r/min to obtain fermentation liquor;
(3) Centrifuging the fermentation liquor obtained in the step (2) at 3000r/min for 10min, carrying out solid-liquid separation to obtain a precipitate and a supernatant I, placing the precipitate in a sterile tube, adding anhydrous methanol, carrying out ultrasonic extraction for 3h at 30 ℃ and 500W, cooling to room temperature, centrifuging at 12000r/min for 10min, separating to obtain a supernatant II, repeatedly extracting for 3 times, mixing the supernatant II each time, filtering through a microporous filter membrane of 0.22 mu m to obtain a filtrate, freeze-drying the filtrate, and grinding the filtrate into powder to obtain the microbial fermentation preparation.
Example 3: the embodiment provides a fatty acid-valienamine-hexoside compound, and a preparation method of the fatty acid-valienamine-hexoside compound, which comprises the following steps:
I. mixing valienamine and fatty acid in a molar ratio of 1:1, adding deionized water, adjusting pH to 8 with sodium bicarbonate, maintaining the temperature at 50deg.C, and stirring for 30min to obtain a reactant I;
adding the supernatant I obtained in the step (3) in the example 1 and phytic acid into the reactant I obtained in the step I, regulating the pH to 11 by using 1mol/L NaOH, stirring and heating to 100 ℃, heating for 4 hours, concentrating to 20% of the original volume at 60 ℃, and then spray drying to obtain powder;
III, mixing the powder obtained in the step II with ethyl acetate according to a mass ratio of 1:3, stirring for 1: 1h, filtering, and concentrating filtrate to dryness under the absolute pressure of 0.08MPa to obtain a crude extract;
and IV, performing silica gel column chromatography on the crude extract obtained in the step III, eluting with eluent with the volume ratio of cyclohexane to ethyl acetate of 70:30, performing medium-low pressure liquid-phase ODS column chromatography, eluting with eluent with the volume ratio of methanol to water of 90:10, taking a part of the eluent, analyzing by a superconducting nuclear magnetic resonance spectrometer, concentrating the rest of the eluent under the absolute pressure of 0.08MPa until the rest of the eluent is dry, and obtaining the fatty acid-valienamine-hexoside compound when eluting, wherein the flow rate of the eluent is 3 mL/min.
The mass ratio of valienamine to deionized water in the step I of the embodiment is 1:10, and the fatty acid is linoleic acid; the volume ratio of the reactant I to the supernatant I to the phytic acid in the step II is 20:60:1; FIG. 1 is a nuclear magnetic resonance spectrum of a fatty acid-valienamine-hexoside compound prepared in this example, which shows that the molecular formula of the compound is C 32 H 56 N 2 O 8 The structural formula is shown in figure 2.
Example 4: the embodiment provides a fatty acid-valienamine-hexoside compound, and a preparation method of the fatty acid-valienamine-hexoside compound, which comprises the following steps:
I. mixing valienamine and fatty acid in a molar ratio of 1:1, adding deionized water, adjusting pH to 7.5 with sodium bicarbonate, maintaining the temperature at 40deg.C, and stirring for 30min to obtain a reactant I;
adding the supernatant I obtained in the step (3) in the example 1 and phytic acid into the reactant I obtained in the step I, regulating the pH to 10 by using 1mol/L NaOH, stirring and heating to 100 ℃, heating for 4 hours, concentrating to 20% of the original volume at 60 ℃, and then spray drying to obtain powder;
III, mixing the powder obtained in the step II with ethyl acetate according to a mass ratio of 1:3, stirring for 1: 1h, filtering, and concentrating filtrate to dryness under the absolute pressure of 0.08MPa to obtain a crude extract;
and IV, performing silica gel column chromatography on the crude extract obtained in the step III, eluting with eluent with the volume ratio of cyclohexane to ethyl acetate of 70:30, performing medium-low pressure liquid-phase ODS column chromatography, eluting with eluent with the volume ratio of methanol to water of 90:10, concentrating to dryness under the absolute pressure of 0.08MPa, and eluting with the flow rate of 3mL/min to obtain the fatty acid-valienamine-hexoside compound.
The mass ratio of valienamine to deionized water in the step I of the embodiment is 1:10, and the fatty acid is alpha-linolenic acid; the volume ratio of the reactant I, the supernatant I and the phytic acid in the step II is 20:60:1.
Example 5: the embodiment provides a natural immunomodulator, which comprises a biological fermentation preparation and a fatty acid-valienamine-hexoside compound, and also provides a preparation method of the natural immunomodulator, which comprises the following steps: the microbial fermentation preparation prepared in example 1 and the fatty acid-valienamine-hexoside compound prepared in example 3 are uniformly mixed in a mixer according to a mass ratio of 5:1 to prepare the natural immunomodulator.
Comparative example 1: the comparative example provides a natural immunomodulator comprising a traditional Chinese medicine preparation and a fatty acid-valienamine-hexoside compound.
The preparation method of the traditional Chinese medicine preparation comprises the following steps: mixing and cleaning radix Tripterygii Wilfordii, radix Paeoniae alba and Corni fructus at a mass ratio of 5:1:1, drying and pulverizing at 55deg.C, sieving with 80 mesh sieve to obtain Chinese medicinal powder, placing in a sterile tube, adding anhydrous methanol, extracting with 2 g/15 mL of Chinese medicinal powder at 30deg.C and 500W by ultrasound for 4 hr, cooling to room temperature, centrifuging at 12000r/min for 10min, separating to obtain supernatant II, repeatedly extracting for 3 times, mixing the supernatant II, filtering with 0.22 μm microporous membrane to obtain filtrate, lyophilizing the filtrate, and grinding into powder to obtain the final product.
The preparation method of the fatty acid-valienamine-hexoside compound is the same as that of example 3.
The comparative example also provides a preparation method of the natural immune modulator, which comprises the following steps: uniformly mixing the traditional Chinese medicine preparation and the fatty acid-valienamine-hexoside compound in a mass ratio of 5:1 in a mixer to prepare the natural immune regulator.
Comparative example 2: the present comparative example provides a natural immunomodulator comprising a fatty acid-valienamine reactant and a microbial fermentation formulation.
The preparation method of the fatty acid-valienamine reactant comprises the following steps: mixing valienamine and fatty acid in a molar ratio of 1:1, adding deionized water, adjusting pH to 7.5 with sodium bicarbonate, maintaining at 40deg.C, stirring for 30min, concentrating at 60deg.C to 20% of the original volume, and spray drying to obtain fatty acid-valienamine reactant.
The preparation method of the microbial fermentation preparation is the same as that of example 1.
The comparative example also provides a preparation method of the natural immune modulator, which comprises the following steps: the microbial fermentation preparation and the fatty acid-valienamine reactant are uniformly mixed in a mixer according to the mass ratio of 5:1, so as to prepare the natural immunomodulator.
Experimental example 1: the natural immunomodulators of example 5 and comparative examples 1-2 were each mixed with deionized water to prepare 0.1g/mL solutions. 50 SPF-class Kunming mice were selected, male, 7-9 weeks old, weighing (20+ -2) g, 40 of which were used as model groups, after 1 week of feeding with sterile distilled water, 3wt% DSS solution was used instead of sterile distilled water, 7 d was continued, the new DSS solution was changed daily, during which 10 other mice were used as blank groups to be fed with sterile distilled water daily, and then 40 mice of the model groups were divided into example 5 group, comparative example 1 group, comparative example 2 group and CK group, 10 of each group were respectively filled with the solutions prepared by the natural immunomodulators prepared in example 5, comparative example 1, comparative example 2 and an equal volume of sterile saline for a fixed time per day, the blank groups were filled with an equal volume of sterile saline at the same time, 16 days continuously, 1 time per day, and the mice of each group were free to drink water during the test. Mice begin fasted at the end of the 15d gavage and are sacrificed 2h after the end of the 16d gavage. The colon tissue of the mice was taken, the intestinal lumen was flushed clean with normal saline, and about 0.1g of the colon tissue was placed in liquid nitrogen for preservation. Colon tissues of 5 mice are randomly picked in each group, and before detection, the colon tissues are homogenized according to the mass ratio of PBS=1:9; centrifuging the prepared homogenate at 3000r/min for 10min, absorbing supernatant, detecting the indexes of mouse TNF-alpha and IL-17 by using an ELISA kit, and carrying out the specific operation steps strictly according to the specification of the kit. The results are shown in FIGS. 3-4.
From FIGS. 3-4, the levels of TNF-. Alpha.and IL-17 were significantly increased in the colon of the CK mice compared to the blank mice. The cytokines TNF-. Alpha.and IL-17 content were extremely significantly reduced in the groups of example 5 and comparative examples 1-2 compared to the CK group. * Indicates a very significant difference compared to the blank group, # indicates a very significant difference compared to the CK group.
The results in FIGS. 3-4 show that the natural immunomodulators of example 5 and comparative examples 1-2 have different degrees of down-regulation of the levels of pro-inflammatory factors TNF- α, IL-17 in colon tissue, as best seen in group 5 of examples. The content of pro-inflammatory factors TNF-alpha and IL-17 in colon tissues of the CK group mice is obviously increased, which indicates that the colon of the CK group mice has serious inflammatory reaction, and the natural immunomodulator can improve abnormal changes of various cytokines and tends to restore balance. The natural immunomodulator has the effect of inhibiting the expression of TNF-alpha and IL-17, and can be used as immunomodulator for preventing and treating immune related diseases, such as autoimmune diseases like rheumatoid arthritis.
Experimental example 2: placing human normal liver cell L02 at 37deg.C, and containing 5% CO 2 In the cell culture chamber of (2), RPMI-1640 medium containing 10% fetal bovine serum is used as a complete medium, every 60h passage is carried out, 10000 normal human liver cells L02 in logarithmic growth phase are inoculated into a 96-well plate per 100 mu L of each well, the average of the wells of the 96-well plate is divided into 4 groups, the natural immune regulator prepared in the example 5 and the comparative example 1-2 is respectively added, the concentration of each well is 2 mu g/mL, and a blank control group without the natural immune regulator is simultaneously arranged. Placing each group at 37deg.C, and containing 5% CO 2 Is cultured in a cell culture incubator for 48 hours. Cell absorbance values were determined using CCK-8 kit according to formula C (%) = [ (a) c -A 0 )/(A b -A 0 )]*100% of calculated cell viability, C is cell viability, A c For the absorbance values of the test group, A b For the absorbance value of the control group, A 0 Is the background absorbance value. The results are shown in FIG. 5. * Indicating a very significant difference compared to the blank control group, indicating a significant difference compared to the control group.
As can be seen from the results of FIG. 5, the cell viability of the example 5 group is not significantly changed compared with that of the blank control group, the cell viability of the comparative examples 1-2 group is significantly reduced compared with that of the control group, and the attenuation effect is poor, which indicates that the natural immunomodulator has lower cytotoxicity and is safer and more reliable.
Those of ordinary skill in the art will appreciate that: the discussion of any of the embodiments above is merely exemplary and is not intended to suggest that the scope of the invention (including the claims) is limited to these examples; the technical features of the above embodiments or in the different embodiments may also be combined within the idea of the invention, the steps may be implemented in any order and there are many other variations of the different aspects of the invention as described above, which are not provided in detail for the sake of brevity.
The present invention is intended to embrace all such alternatives, modifications and variances which fall within the broad scope of the appended claims. Therefore, any omission, modification, equivalent replacement, improvement, etc. of the present invention should be included in the scope of the present invention.
Claims (4)
1. A natural immunomodulator, which is characterized by comprising a microbial fermentation preparation and fatty acid-valienamine-hexoside;
the preparation method of the microbial fermentation preparation comprises the following steps:
(1) Mixing and cleaning radix Tripterygii Wilfordii, radix Paeoniae alba and Corni fructus at a mass ratio of 5:1:1, drying and pulverizing at 55deg.C, sieving with 80 mesh sieve, mixing with water, sterilizing at 121deg.C for 30min, and adding K 2 HPO 4 、KH 2 PO 4 NaCl and MgSO 4 The addition amounts are respectively 0.7 g/L, 0.3 g/L, 0.5g/L and 0.5g/L, so as to obtain a fermentation culture medium;
(2) Inoculating Trichoderma harzianum, aeromonas hydrophila and bacillus mycoides into the fermentation culture medium obtained in the step (1), wherein the inoculum size is 5%, the fermentation temperature is 26-30 ℃, and the shaking table is cultivated for 96 hours at the rotation speed of a shaking table of 150-200r/min to obtain fermentation liquor;
(3) Centrifuging the fermentation liquor obtained in the step (2) for 10min at 3000r/min, carrying out solid-liquid separation to obtain a precipitate and a supernatant I, placing the precipitate in a sterile tube, adding anhydrous methanol, carrying out ultrasonic extraction on the precipitate and the anhydrous methanol for 3-4h at the mass volume ratio of 2g to 15mL, cooling to room temperature, centrifuging for 10min at 12000r/min, separating to obtain a supernatant II, repeatedly extracting for 3 times, mixing the supernatant II each time, filtering through a microporous filter membrane of 0.22 mu m to obtain a filtrate, freeze-drying the filtrate, and grinding the filtrate into powder to obtain the microbial fermentation preparation;
the fatty acid-valienamine-hexoside comprises a fatty acid-valienamine-hexoside compound or a pharmaceutically acceptable salt, solvate or hydrate thereof;
the structural formula of the fatty acid-valienamine-hexoside compound is shown as formula 1:
formula 1;
the R1 group in formula 1 is CH 3 (CH 2 ) 4 CH=CHCH 2 CH=CH(CH 2 ) 7 —、
CH 3 (CH 2 ) 4 CH=CHCH 2 CH=CHCH 2 CH =CH(CH 2 ) 7 —、
CH 3 (CH 2 ) 4 (CH=CH-CH 2 ) 4 (CH 2 ) 2 -at least one of;
the preparation method of the fatty acid-valienamine-hexoside compound comprises the following steps:
I. mixing valienamine and fatty acid in a molar ratio of 1:1, adding deionized water, adjusting pH to 7.5-8 with sodium bicarbonate, maintaining the temperature at 40-50deg.C, and stirring for 30min to obtain a reactant I;
adding the supernatant I and phytic acid obtained in the step (3) into the reactant I obtained in the step I, regulating the pH to 10-11 by using 1mol/L NaOH, stirring and heating to 100 ℃, heating for 4 hours, concentrating to 20% of the original volume at 60 ℃, and then spray drying to obtain powder;
III, mixing the powder obtained in the step II with ethyl acetate according to a mass ratio of 1:3, stirring for 1h, filtering, and concentrating filtrate to dryness under the absolute pressure of 0.08MPa to obtain a crude extract;
and IV, performing silica gel column chromatography on the crude extract obtained in the step III, eluting with eluent with the volume ratio of cyclohexane to ethyl acetate of 70:30, performing medium-low pressure liquid-phase ODS column chromatography, eluting with eluent with the volume ratio of methanol to water of 90:10, concentrating to dryness under the absolute pressure of 0.08MPa, and eluting with the flow rate of 3mL/min to obtain the fatty acid-valienamine-hexoside compound.
2. The natural immune modulator according to claim 1, wherein in the step I, the mass ratio of valienamine to deionized water is 1:10, and the fatty acid is at least one of linoleic acid, alpha-linolenic acid and tetraarachidonic acid; the volume ratio of the reactant I, the supernatant I and the phytic acid in the step II is 20:60:1.
3. A natural immune modulator according to claim 2, wherein the pharmaceutically acceptable salt is a salt of a compound of formula 1 with an organic or inorganic base, and the salt formed is a sodium, potassium, calcium, iron, magnesium, zinc, aluminum, barium or ammonium salt; the pharmaceutically acceptable solvate is a solution formed by dissolving a compound of formula 1 in a solvent; the pharmaceutically acceptable hydrate is a hydrate formed by combining a compound of formula 1 with water molecules in a covalent bond.
4. A method of preparing a natural immunomodulatory agent according to any one of claims 1-3 comprising the steps of: uniformly mixing the microbial fermentation preparation and fatty acid-valienamine-hexoside in a mass ratio of 5:1 in a mixer to prepare the natural immunomodulator.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311595881.1A CN117298177B (en) | 2023-11-28 | 2023-11-28 | Natural immunomodulator and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311595881.1A CN117298177B (en) | 2023-11-28 | 2023-11-28 | Natural immunomodulator and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN117298177A CN117298177A (en) | 2023-12-29 |
| CN117298177B true CN117298177B (en) | 2024-02-02 |
Family
ID=89273949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311595881.1A Active CN117298177B (en) | 2023-11-28 | 2023-11-28 | Natural immunomodulator and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117298177B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478565A (en) * | 2021-12-08 | 2022-05-13 | 安徽农业大学 | Monascus A with glycosidase inhibiting activity and immunoregulation activity and preparation method thereof |
| WO2023216885A1 (en) * | 2022-05-13 | 2023-11-16 | 山东恒鲁生物科技有限公司 | Polypeptide having glycoside hydrolase activity, preparation method therefor, and use thereof |
-
2023
- 2023-11-28 CN CN202311595881.1A patent/CN117298177B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114478565A (en) * | 2021-12-08 | 2022-05-13 | 安徽农业大学 | Monascus A with glycosidase inhibiting activity and immunoregulation activity and preparation method thereof |
| WO2023216885A1 (en) * | 2022-05-13 | 2023-11-16 | 山东恒鲁生物科技有限公司 | Polypeptide having glycoside hydrolase activity, preparation method therefor, and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 42种中草药对嗜水气单胞菌的体外抑菌试验;罗新;张其中;;淡水渔业;41(03);第61-65页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN117298177A (en) | 2023-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112999261B (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
| KR100813914B1 (en) | The conversion and modification of natural medicines by intestinal probiotics co-fermentation cultures | |
| CN111040044B (en) | Cordyceps militaris intracellular polysaccharide, preparation method and application thereof in regulating intestinal flora | |
| CN101249259B (en) | High content and high activity oral polysaccharide-peptide and preparing method and application of the same | |
| CN104522750A (en) | Alga healthcare food | |
| CN103301321B (en) | Thrombolytic active polysaccharide mixture preparation technology | |
| CN110437247B (en) | Mixed source terpenoid with liver protection function and application thereof | |
| CN117298177B (en) | Natural immunomodulator and preparation method thereof | |
| CN116211956A (en) | Composition for regulating intestinal tract and/or improving obesity, preparation method, chewable tablet and application thereof | |
| CN113621673B (en) | Method for fermenting ginseng by composite strain, fermentation product and application | |
| CN110923101A (en) | Processing method of six-ingredient rehmannia health wine | |
| CN115477693A (en) | Two cyclic peptide compounds derived from marine fungi, preparation method thereof and application thereof in preparing anti-inflammatory drugs | |
| CN112961259B (en) | Preparation method of taurolimus polysaccharide and application of taurolimus polysaccharide in field of improving intestinal function | |
| CN101396373A (en) | Cinobufacini extract and preparation method thereof | |
| CN111150754B (en) | Application of chestnut flower extract in preparation of food or anti-inflammatory drugs | |
| CN113243532A (en) | Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof | |
| CN111449241A (en) | Method for improving antioxidant capacity of sea cucumber saponin extracting solution | |
| CN1146915A (en) | Compound anticancer, its preparing process and use | |
| CN114195907B (en) | Low-molecular-weight spirulina polysaccharide and preparation method and application thereof | |
| CN108103113B (en) | Preparation method of food and medicine fungus fermentation product rich in stilbene compounds | |
| CN115433703B (en) | Application of capsaicin in promoting proliferation of akkermansia muciniphila | |
| CN114681573B (en) | Method for preparing traditional Chinese medicine by utilizing composite microorganism fermentation liquor, composition and application thereof | |
| CN116270908B (en) | Application of vetiver product in preparation of medicines for improving animal immunity and resisting inflammation | |
| CN117297089A (en) | Lipid-lowering composition comprising polyphenol extract and oligosaccharide extract and preparation method thereof | |
| CN115491280A (en) | Roxburgh rose enzymatic fruit vinegar and preparation process and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |